natgillin/translations-raw huggingface dataset:
Alanine aminotransferase (ALT) or serum glutamopyruvate transferase (SGPT) and a complete blood cell count, including a differential white blood cell count and a platelet count, must be checked simultaneously and with the same frequency: 
Alanin-aminotransferazo (ALT) oz. serumsko glutamat-piruvat-transferazo (SGPT) in celotno krvno sliko, vključno z diferencialno belo krvno sliko in številom trombocitov, je treba preveriti sočasno in z enako pogostnostjo:
- Reduction in the number of white blood cells, which makes infections more likely (leucopenia). 
- hudo zmanjšanje števila belih krvnih celic, kar lahko poveča možnosti infekcij (levkopenija),
A tuberculin reaction test should be considered for those patients with other tuberculosis risk factors. 
Pri bolnikih z drugimi dejavniki tveganja za tuberkulozo, je potrebno upoštevati tuberkulinski kožni test.
Alternatively, 50 g of activated powdered charcoal is administered 4 times daily. 
Druga možnost je uporaba 50 g aktivnega oglja v prahu, 4-krat na dan.
The Marketing Authorisation Holder (MAH) shall ensure that all physicians who are expected to prescribe/use Leflunomide Teva are provided with a physician educational pack containing the 
Imetnik dovoljenja za promet bo poskrbel, da bodo vsi zdravniki, ki nameravajo predpisovati zdravilo Leflunomide Teva dobili izobraževalno gradivo, ki vsebuje:
Marketing Authorisation Holder: Teva Pharma B.V. 
Imetnik dovoljenja za promet Teva Pharma B.V.
- Cutaneous lupus (characterized by rash/erythema on skin areas that are exposed to light) 
- kožni lupus (značilen izpuščaj/eritem na predelih kože, ki so izpostavljeni svetlobi),
Leflunomide was administered as a single oral 100 mg dose to 3 haemodialysis patients and 3 patients on continuous peritoneal dialysis (CAPD). 
Leflunomid so aplicirali v enkratnem peroralnem 100 mg odmerku 3 hemodializnim bolnikom in 3 bolnikom na kontinuirani ambulantni peritonealni dializi (CAPD).
At a dose level of 20 mg/day, average plasma concentration of A771726 at steady state is approximately 35 μg/ml. 
Pri odmerku 20 mg/dan je bila povprečna plazemska koncentracija A771726 v stanju dinamičnega ravnotežja približno 35 μg/ml.
The results of a population pharmacokinetic analysis of these trials have demonstrated that pediatric patients with body weights ≤ 40 kg have a reduced systemic exposure (measured by Css) of A771726 relative to adult rheumatoid arthritis patients (see section 
Rezultati populacijske farmakokinetične analize teh preskušanj so pokazali, da je pri pediatričnih bolnikih s telesno maso ≤ 40 kg sistemska izpostavljenost A771726 (merjena s Css) manjša kot pri odraslih bolnikih z revmatoidnim artritisom (glejte poglavje 4.2).
This medicinal product contains lactose (see leaflet for further information). 
SEZNAM POMOŽNIH SNOVI To zdravilo vsebuje laktozo (za dodatne informacije glejte Navodilo za uporabo).
Due to the very long half-lifeof A771726 (approximately 2 weeks), a loading dose of 100 mg for 3 days was used in clinical studies to facilitate the rapid attainment of steady-state levels of A771726. 
Zaradi zelo dolgega razpolovnega časa A771726 (približno 2 tedna) so v kliničnih študijah 3 dni uporabljali udarni odmerek 100 mg, da so pospešili hitro doseganje koncentracij A771726 v stanju dinamičnega ravnotežja.
Since such therapy can lead to additive or even synergistic toxicity (e.g. hepato- or haematotoxicity), combination with another DMARD (e.g. methotrexate) is not advisable. 
Ker lahko takšno zdravljenje povzroči aditivne ali celo sinergistične (npr. hepato- ali hemato-) toksične učinke, kombiniranje z drugimi imunomodulirajočimi antirevmatičnimi zdravili (npr. z metotreksatom) ni priporočljivo.
Leflunomide Teva is used to treat adult patients with active rheumatoid arthritis. 
Zdravilo Leflunomid Teva se uporablja za zdravljenje odraslih bolnikov z aktivnim revmatoidnim artritisom.
The Marketing Authorisation Holder (MAH) shall ensure that any changes to the safety profile of the reference medicinal product requiring changes to the Risk Management Plan or Product Information are immediately implemented for Leflunomide Teva. 
Imetnik dovoljenja za promet z zdravilom zagotavlja, da bodo kakršnekoli spremembe v varnostnem profilu referenčnega zdravila, ki bi zahtevale spremembe Načrta za obvladovanje tveganja ali
- Hepatitis (inflammation of the liver). 
- hepatitis (vnetje jeter),
Ask your doctor or pharmacist for advice before taking any medicine. 
Posvetujte se z zdravnikom, preden vzamete katerokoli zdravilo.
Administration of activated charcoal (powder made into a suspension) orally or via nasogastric tube (50 g every 6 hours for 24 hours) has been shown to reduce plasma concentrations of the active metabolite A771726 by 37 % in 24 hours and by 48 % in 48 hours. 
Dokazano je, da uporaba aktivnega oglja (prašek, pripravljen v suspenziji) peroralno ali po nazogastrični sondi (50 g na 6 ur v 24 urah) zniža plazemsko koncentracijo aktivnega presnovka A771726 za 37% v 24 urah in za 48% v 48 urah.
Leflunomide Teva is contraindicated in patients with severe hypoproteinaemia or impairment of liver function (see section 4.3). 
Zdravilo Leflunomid Teva je kontraindicirano pri bolnikih s hudo hipoproteinemijo ali okvarjenim delovanjem jeter (glejte poglavje 4.3).
An in vivo interaction study with cimetidine (non-specific cytochrome P450 inhibitor) has demonstrated a lack of a significant interaction. 
Študija interakcij s cimetidinom (nespecifičnim zaviralcem citokroma P450) in vivo ni pokazala pomembnega medsebojnega delovanja.
The symptoms include inflammation of joints, swelling, difficulty moving and pain. 
Simptomi revmatoidnega artritisa vključujejo vnetje sklepov, zatekanje, težko premikanje in bolečine.
This 2 years may be reduced to a few weeks if you take a treatment, recommended by your doctor, which speeds up removal of Leflunomide Teva 
To obdobje je mogoče skrajšati na nekaj tednov z jemanjem določenih zdravil, ki vam jih bo priporočil zdravnik in ki pospešijo odstranjevanje zdravila Leflunomid Teva iz telesa.
• Pregnant women, or women of childbearing potential who are not using reliable contraception during treatment with leflunomide and thereafter as long as the plasma levels of the active metabolite are above 0.02 mg/l (see section 4.6). 
• Nosečnice in ženske v rodni dobi, ki med zdravljenjem z leflunomidom ne uporabljajo zanesljive kontracepcije; to velja tudi še po zdravljenju, vse dokler je plazemska koncentracija aktivnega presnovka nad 0,02 mg/l (glejte poglavje 4.6).
Similarly, recent treatment with hepatotoxic or haematotoxic medicinal products (e.g. methotrexate) may result in increased side effects; therefore, the initiation of leflunomide treatment has to carefully be considered regarding these benefit/risk aspects and closer monitoring is recommended in the initial 
Podobno lahko nedavno zdravljenje s hepatotoksičnimi ali hematotoksičnimi zdravili (npr. z metotreksatom) zveča tveganje za pojav neželenih učinkov; zato je treba uvedbo zdravljenja z leflunomidom skrbno pretehtati upoštevaje koristi in tveganja; v začetnem obdobju po zamenjavi je priporočljivo natančnejše nadziranje.
For any information about this medicine, please contact the local representative of the Marketing 
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom.
As soon as skin and/or mucosal reactions are observed which raise the suspicion of such severe reactions, Leflunomide Teva and any other possibly associated treatment must be discontinued, and a leflunomide washout procedure initiated immediately. 
Čim se na koži in/ali sluznici pojavijo reakcije, ki zbujajo sum na takšne hude reakcije, je treba prekiniti uporabo zdravila Leflunomid Teva in drugih zdravil, ki bi jih lahko povzročila, in takoj začeti postopek izpiranja.
It contains the 
Kaj vsebuje navodilo:
HDPE containers: Do not store above 30°C. 
HDPE vsebniki: Shranjujte pri temperaturi do 30°C.
- Severe infections (including sepsis), which may be fatal. 
- hude okužbe (vključno s sepso), ki so lahko usodne,
You will normally take Leflunomide Teva over long periods of time. 
Običajno boste zdravilo Leflunomid Teva jemali dolgo časa.
Leflunomide is indicated for the treatment of adult patients with active rheumatoid arthritis as a "disease modifying antirheumatic drug" (DMARD). 
Leflunomid je indiciran za zdravljenje odraslih bolnikov z aktivnim revmatoidnim artritisom kot imunomodulirajoče antirevmatično zdravilo ("disease-modifying antirheumatic drug" (DMARD)).
Rheumatoid arthritis is a crippling form of arthritis. 
Revmatoidni artritis je oblika artritisa z ohromelostjo.
What Leflunomide Teva is and what it is used for What you need to know before you take Leflunomide Teva 
Kaj je zdravilo Leflunomid Teva in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Leflunomid Teva Kako jemati zdravilo Leflunomid Teva
Very rare side effects (may affect up to 1 in 10,000 people) - An infection characterised by high fever, sore throat, skin lesions and an extreme reduction of white blood cells (agranulocytosis). 
Zelo redki neželeni učinki (prizadanejo lahko največ 1 od 10.000 ljudi) - infekcija, za katero je značilna visoka vročina, boleče grlo, rane na koži in izrazito zmanjšanje belih krvnih celic (agranulocitoza),
Men wishing to father a child should contact their doctor who may advise them to stop taking Leflunomide Teva and take certain medicines to remove Leflunomide Teva rapidly and sufficiently from their body. 
Moški ki želijo zaploditi otroka, se morajo posvetovati z zdravnikom, ki jjim bo morda svetoval, da nehajo jemati zdravilo Leflunomid Teva in vzamejo določena zdravila za hitro in uspešno izločanje zdravila Leflunomid Teva iz telesa.
The main effects were anaemia, leucopenia, decreased platelet counts and panmyelopathy and reflect the basic mode of action of the compound (inhibition of DNA synthesis). 
Glavni učinki so bili anemija, levkopenija, zmanjšanje števila trombocitov in panmielopatija; učinki odražajo temeljni način delovanja spojine
The use of leflunomide with antimalarials used in rheumatic diseases (e.g. chloroquine and hydroxychloroquine), intramuscular or oral gold, D-penicillamine, azathioprine and other immunosuppressive agents including Tumour Necrosis Factor alpha-Inhibitors has not been adequately studied up to now in randomised trials (with the exception of methotrexate, see section 4.5). 
Uporaba leflunomida z antimalariki, ki se uporabljajo pri revmatičnih boleznih (npr. s klorokinom ali hidroksiklorokinom), intramuskularnim ali peroralnim zlatom, D-penicilaminom, azatioprinom in drugimi imunosupresivnimi zdravili, vključno z zaviralci tumorje nekrotirajočih faktorjem alfa, doslej v randomiziranih preskušanjih ni bila zadosti raziskana (z izjemo metotreksata, glejte poglavje 4.5).
A771726, the active metabolite of leflunomide, inhibits the human enzyme dihydroorotate dehydrogenase (DHODH) and exhibits antiproliferative activity. 
A771726, aktivni presnovek leflunomida, zavira človeški encim dihidroorotat-dehidrogenazo
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE
How to take Leflunomide Teva 
Kako jemati zdravilo Leflunomid Teva
Colestyramine given orally at a dose of 8 g three times a day for 24 hours to three healthy volunteers decreased plasma levels of A771726 by approximately 40 % in 24 hours and by 49 % to 
Holestiramin, uporabljen peroralno v odmerku 8 g trikrat na dan 24 ur je pri treh zdravih prostovoljcih znižal plazemsko koncentracijo A771726 za približno 40% v 24 urah in za 49% do 65% v 48 urah.
Leflunomide Teva is contraindicated in pregnancy (see section 4.3). 
Zdravilo Leflunomid Teva je kontraindicirano med nosečnostjo (glejte poglavje 4.3).
- Inflammation of the small vessels (vasculitis, including cutaneous necrotizing vasculitis). 
- vnetje majhnih žil (vaskulitis, vključno s kožnim nekrotizirajočim vaskulitisom),
- Colestyramine (used to lower cholesterol levels and treat itching associated with jaundice) or activated charcoal as these medicines can reduce the amount of LeflunomideTeva absorbed by your body. 
- holestiramin (uporablja se za zniževanje zvišanega holesterola in za zdravljenje serbečice v povezavi z zlatenico) ali aktivno oglje, saj ti dve zdravili lahko znižata količino zdravila
Rare cases of Progressive Multifocal Leukoencephalopathy (PML) have been reported in patients receiving leflunomide among other immunosuppressants. 
Poročali so o redkih primerih progresivne multifokalne levkoencefalopatije (PML) pri bolnikih, ki so prejemali leflunomid poleg ostalih zdravil z imunosupresivnim delovanjem.
- If you develop swollen spongy gums, ulcers, and loose teeth (an infectious mouth disease known as ulcerative stomatitis) then you should contact your doctor who may advise you to stop 
- če se pri vas pojavijo gobaste dlesni, razjede in izguba zob (infekcijska ustna bolezen, znana kot ulcerativni stomatitis), obvestite svojega zdravnika, ki vam bo morda svetoval prenehanje jemanja zdravila Leflunomid Teva.
Caution is advised when leflunomide is given together with drugs, other than NSAIDs, metabolised by CYP2C9 such as phenytoin, warfarin, phenprocoumon and tolbutamide. 
Previdnost je potrebna, če se leflunomid uporablja skupaj z drugimi zdravili (razen nesteroidni antirevmatiki), ki se presnavljajo s CYP2C9, npr. s fenitoinom, varfarinom, fenprokumonom ali tolbutamidom.
• Hypersensitivity to the active substance (especially previous Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme) or to any of the excipients listed in section 6.1. 
• Preobčutljivost za zdravilno učinkovino (posebno s predhodnim Stevens-Johnsonovim sindromom, toksično epidermalno nekrolizo, multiformnim eritemom) ali katerokoli pomožno snov, navedeno v poglavju 6.
Leflunomide Teva passes into breast milk. 
Zdravilo Leflunomid Teva prehaja v materino mleko.
If you think you may be pregnant while you are taking Leflunomide Teva, contact your doctor immediately for a pregnancy test. 
Če med jemanjem zdravila Leflunomid Teva posumite, da ste morda noseči, morate o tem nemudoma obvestiti svojega zdravnika in opraviti nosečnostni test.
• When new information is received that may impact on the current Safety Specification, 
• če se pridobijo novi podatki, ki lahko vplivajo na trenutne podatke o varnosti, načrt farmakovigilance ali aktivnosti za zmanjševanje tveganja.
If you are already taking non-steroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids, you may continue to use these after starting Leflunomide Teva. 
Če že jemljete nesteroidna protivnetna zdravila (NSAID) ali kortikosteroide ali oboje, lahko z njimi nadaljujete tudi po začetku uporabe zdravila Leflunomid Teva.
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product 
Izdaja zdravila je le pod omejenimi pogoji in na recept (glej Priloga I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
Leflunomide is a disease-modifying anti-rheumatic agent with antiproliferative properties. 
Leflunomid je imunomodulirajoče antirevmatično zdravilo z antiproliferacijskimi lastnostmi.
If you are pregnant or become pregnant while taking Leflunomide Teva, the risk of having a baby with serious 
Če ste noseči ali zanosite med jemanjem zdravila Leflunomid Teva, je povečano tveganje, da se rodi otrok z resnimi prirojenimi okvarami.
- Low blood levels of potassium which can cause muscle weakness, twitching or abnormal heart - An increase in the levels of fat in the blood (cholesterol and triglycerides). 
- nizke koncentracije kalija v krvi, kar lahko vodi v mišično slabotnost, trzanje ali nenormalni srčni ritem, - zvečanje koncentracije maščob v krvi (holesterola in trigliceridov),
Interstitial lung disease has been reported during treatment with leflunomide (see section 4.8). 
Med zdravljenjem z leflunomidom je bila opisana intersticijska bolezen pljuč (glejte poglavje 4.8).
cutaneous lupus erythematosus, pustular psoriasis or worsening psoriasis Musculoskeletal and connective tissue disorders Common: 
kožni eritematozni lupus, postulozna psoriaza ali njeno poslabšanje Bolezni mišično-skeletnega sistema in vezivnega tkiva Pogosti:
If the patient is already receiving nonsteroidal anti-inflammatory drugs (NSAIDs) and/or corticosteroids, these may be continued after starting leflunomide. 
Če bolnik že dobiva nesteroidne antirevmatike (NSAR), kortikosteroide ali oboje, jih lahko po začetku jemanja leflunomida uporablja še naprej.
Leflunomide Teva can occasionally cause some problems with your blood, liver, lungs or nerves in your arms or legs. 
Občasno lahko zdravilo Leflunomid Teva povzroči nekatere krvne, jetrne, pljučne težave ali težave z živci v rokah in nogah.
Male patients should be aware of the possible male-mediated foetal toxicity. 
Moški bolniki se morajo zavedati možnih toksičnih učinkov za plod, ki jih lahko posreduje moški
Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit/risk aspects. 
Nedavno ali sočasno zdravljenje s hepatotoksičnimi ali hematotoksičnimi imunomodulirajočimi antirevmatičnimi zdravili (npr. z metotreksatom) lahko poveča tveganje za resne neželene učinke; zato je treba pri uvedbi leflunomida skrbno pretehtati korist in tveganje tega zdravljenja.
- Pain, swelling and tenderness most often in the hand or wrist. 
- bolečina, otekanje in občutljivost, najpogosteje rok in zapestij,
14C-leflunomide in three healthy volunteers, no unchanged leflunomide was detected in plasma, urine or faeces. 
3 zdravih prostovoljcih v plazmi, urinu ali blatu niso našli nespremenjenega leflunomida.
Contains lactose (see leaflet for further information). 
SEZNAM POMOŽNIH SNOVI Vsebuje tudi laktozo (za dodatne informacije glejte navodilo za uporabo).
This metabolite is responsible for essentially all the in vivo activity of leflunomide. 
Ta je odgovoren za praktično vso aktivnost leflunomia in- vivo.
All elevations resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide. 
V vseh primerih je zvišanje izginilo, pri 2 bolnikih ob nadaljevanju uporabe obeh zdravil in pri 3 po opustitvi leflunomida.
In clinical trials no safety problems were observed when leflunomide and NSAIDs metabolised by CYP2C9 were co-administered. 
V kliničnih preskušanjih med sočasno uporabo leflunomida in nesteroidnih antirevmatikov, ki se presnavljajo s CYP2C9, ni bilo težav z varnostjo.
If both plasma concentrations are below 0.02 mg/l, and after a waiting period of at least 3 months, the risk of 
Če je ta koncentracija v obeh primerih manjša od 0,02 mg/l in po vsaj 3-mesečnem čakalnem obdobju, je tveganje toksičnosti za plod zelo majhno.
In case of severe haematological reactions, including pancytopenia, Leflunomide Teva and any concomitant myelosuppressive treatment must be discontinued and a leflunomide washout procedure initiated. 
V primeru hudih hematoloških reakcij, vključno s pancitopenijo, je treba prekiniti uporabo zdravila Leflunomid Teva in morebitnih drugih mielosupresivnih zdravil ter začeti postopek izpiranja leflunomida.
A771726 plasma levels can be expected to be above 0.02 mg/l for a prolonged period. 
Pričakovati je mogoče, da bo plazemska koncentracija A771726 dolgo časa nad 0,02 mg/l.
- If you get any side effects , talk to your doctor, pharmacist or nurse. 
- Če opazite katerikoli neželeni učinek, se posvetujte s svojim zdravnikom, s farmacevtom ali z medicinsko sestro.
For tablets stored in blisters: Do not store above 25°C. 
Tablete shranjene v pretisnih omotih: Shranjujte pri temperaturi do 25°C.
For tablets stored in bottles: Do not store above 30°C. 
Tablete shranjene v plastenkah: Shranjujte pri temperaturi do 30°C.
Increased side effects may occur in case of recent or concomitant use of hepatotoxic or haematotoxic drugs or when leflunomide treatment is followed by such drugs without a washout period (see also guidance concerning combination with other treatments, section 4.4). 
Če se leflunomid uporabi sočasno s hepatotoksičnimi ali hematotoksičnimi zdravili ali če zdravljenju z leflunomidom sledi zdravljenje s takšnimi zdravili brez obdobja izpiranja, se lahko neželeni učinki stopnjujejo (glejte tudi smernice glede kombiniranja z drugimi zdravili, poglavje 4.4).
SPECIAL STORAGE CONDITIONS Do not store above 25°C 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte pri temperaturi do 25°C.
What Leflunomide Teva is and what it is used for 2. 
Kaj je zdravilo Leflunomid Teva in za kaj ga uporabljamo
anaemia, mild thrombocytopenia (platelets < 100 G/l) 
anemija, blaga trombocitopenija (trombociti < 100 x 109/l)
Do not take a double dose to make 
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
However there was a wide variability in final outcome, i.e. in some patients the neuropathy resolved and some patients had persistent symptoms. 
pri nekaterih bolniki je nevropatija izginila, drugi pa so imeli stalne simptome.
• Tablet coating: titanium dioxide, hypromellose, macrogol 400, iron oxide yellow, polysorbate, quinoline yellow aluminium lake and indigo carmine aluminium Lake. 
• Obloga tablete: titanov dioksid, hipromeloza, makrogol 400, rumeni železov oksid, polisorbat, kinolinsko rumeno barvilo in indigotin.
In the phase III trials, the ACR response rates for leflunomide 20 mg/day vs. placebo were 54.6 % vs. 28.6 % (study MN301), and 49.4 % vs. 26.3 % (study US301).After 12 months with active treatment, the ACR response rates in leflunomide patients were 52.3 % (studies MN301/303), 50.5 % (study MN302) and 49.4 % (study US301), compared to 53.8 % (studies MN301/303) in sulphasalazine patients, 64.8 % (study MN302), and 43.9 % (study US301) in methotrexate patients. 
Po 12 mesecih aktivnega zdravljenja so bili deleži odzivov po ACR pri bolnikih na leflunomidu 52,3% (študiji MN301/303), 50,5% (študija MN302) in 49,4% (študija US301) v primerjavi s 53,8% (študiji MN301/303) pri bolnikih na sulfasalazinu ter 64,8% (študija MN302) oz. 43,9% (študija US301) pri bolnikih na metotreksatu.
Blood and lymphatic system disorders Common: 
Bolezni krvi in limfatičnega sistema
White, round film-coated tablets, engraved with “10” on one side and “L” on the other. 
Bela, okrogla filmsko obložena tableta, z vgravirano oznako »10« na eni strani in »L« na drugi strani.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) The risk of malignancy, particularly lymphoproliferative disorders, is increased with use of some 
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi) Uporaba nekaterih imunosupresivnih zdravil poveča nevarnost malignomov, zlasti limfoproliferativnih bolezni.
Leflunomide Teva stored in blisters are available in pack sizes of 28, 30 and 100 film-coated tablets. 
Tablete Leflunomid Teva shranjene v pretisnih omotih so na voljo v pakiranjih po 28, 30 in 100 filmsko obloženih tablet.
If you forget to take Leflunomide Teva In case you forget to take a dose, take it as soon as you remember. 
Če pozabite vzeti odmerek, ga vzemite takoj, ko se spomnite, razen če ni že blizu čas za naslednjega.
Most patients improved after discontinuation of Leflunomide Teva. 
Večini bolnikov se je po prenehanju jemanja zdravila Leflunomid Teva stanje izboljšalo.
The usual starting dose is 100 mg once a day for 3 days. 
Običajni začetni odmerek zdravila Leflunomid Teva je ena 100-mg tableta enkrat na dan prve tri dni.